Page 126 - Read Online

Santillan Hepatoma Res 2020;6:63 I http://dx.doi.org/10.20517/2394-5079.2020.60 Page 13 of 14

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCE
1. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, et al. LI-RADS: a conceptual and historical review from its beginning to its
recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69.
2. Sirlin CB. The LI-RADS adventure-a personal statement. Abdom Radiol (NY) 2018;43:1-2.
3. Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS® algorithm: CT and MRI. Abdom Radiol (NY) 2018;43:111-26.
4. American College of Radiology. Liver Imaging Reporting and Data System version 2018. Available from: http://www.acr.org/Quality-
Safety/Resources/LIRADS. [Last accessed on 12 Aug 2020]
5. Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced
ultrasound. Abdom Radiol (NY) 2018;43:56-74.
6. Ichikawa T, Kitamura T, Nakajima H, Sou H, Tsukamoto T, et al. Hypervascular hepatocellular carcinoma: can double arterial phase
imaging with multidetector CT improve tumor depiction in the cirrhotic liver? AJR Am J Roentgenol 2002;179:751-8.
7. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents,
hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50.
®
8. Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, et al. LI-RADS ancillary features on CT and MRI. Abdom Radiol (NY)
2018;43:82-100.
9. Matsui O, Kobayashi S, Sanada J, Kouda W, Ryu Y, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation
(angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011;36:264-72.
10. Muto J, Shirabe K, Sugimachi K, Maehara Y. Review of angiogenesis in hepatocellular carcinoma. Hepatol Res 2015;45:1-9.
11. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for
hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:149-57.
12. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, et al. Tumor size predicts vascular invasion and histologic grade:
implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-92.
13. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation
of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
14. Kelekis NL, Semelka RC, Worawattanakul S, de Lange EE, Ascher SM, et al. Hepatocellular carcinoma in North America: a
multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J
Roentgenol 1998;170:1005-13.
15. Freeny PC, Baron RL, Teefey SA. Hepatocellular carcinoma: reduced frequency of typical findings with dynamic contrast-enhanced CT
in a non-Asian population. Radiology 1992;182:143-8.
16. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings.
Radiology 1992;183:819-25.
17. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and